Get the Stockscreener App
0.9687
2.38%
-0.0236
After Hours:
.97
0.0013
+0.13%
Coherus Biosciences Inc stock is traded at $0.9687, with a volume of 951.37K.
It is down -2.38% in the last 24 hours and up +21.94% over the past month.
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.
See More
Previous Close:
$0.9923
Open:
$0.9849
24h Volume:
951.37K
Relative Volume:
0.57
Market Cap:
$127.51M
Revenue:
$257.24M
Net Income/Loss:
$-237.89M
P/E Ratio:
-0.3726
EPS:
-2.6
Net Cash Flow:
$-175.17M
1W Performance:
-11.94%
1M Performance:
+21.94%
6M Performance:
+18.86%
1Y Performance:
-54.31%
1-Day Range:
$0.9503
$1.03
1-Week Range:
$0.9174
$1.12
52-Week Range:
$0.6603
$2.43
Coherus Biosciences Inc Stock (CHRS) Company Profile
Name
Coherus Biosciences Inc
Sector
Industry
Phone
(650) 649-3530
Address
C/O DENNIS M. LANFEAR, REDWOOD CITY, CA
Compare CHRS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CHRS
Coherus Biosciences Inc
|
0.9687 | 127.51M | 257.24M | -237.89M | -175.17M | -2.60 |
|
VRTX
Vertex Pharmaceuticals Inc
|
424.99 | 128.84B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
527.78 | 65.38B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
549.65 | 39.67B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.15 | 33.82B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
231.99 | 27.60B | 3.81B | -644.79M | -669.77M | -6.24 |
Coherus Biosciences Inc Stock (CHRS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-16-24 | Downgrade | UBS | Buy → Neutral |
| Nov-17-23 | Initiated | Robert W. Baird | Outperform |
| Nov-08-23 | Downgrade | Maxim Group | Buy → Hold |
| Jul-24-23 | Initiated | Citigroup | Buy |
| May-01-23 | Initiated | Truist | Buy |
| Mar-28-23 | Upgrade | UBS | Neutral → Buy |
| Jun-14-22 | Initiated | UBS | Neutral |
| Mar-07-22 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-16-20 | Initiated | BofA Securities | Neutral |
| Apr-17-20 | Initiated | SunTrust | Buy |
| Aug-13-19 | Initiated | Mizuho | Buy |
| Aug-02-19 | Reiterated | H.C. Wainwright | Buy |
| Aug-02-19 | Reiterated | Maxim Group | Buy |
| Jun-11-19 | Initiated | Barclays | Overweight |
| May-07-19 | Initiated | H.C. Wainwright | Buy |
| Aug-28-18 | Initiated | H.C. Wainwright | Buy |
| Mar-09-18 | Reiterated | Maxim Group | Buy |
| Aug-08-17 | Reiterated | JP Morgan | Overweight |
| Jun-13-17 | Reiterated | Maxim Group | Buy |
| May-05-17 | Initiated | BMO Capital Markets | Outperform |
| Oct-19-16 | Initiated | Robert W. Baird | Outperform |
| Sep-07-16 | Initiated | Maxim Group | Buy |
| Jul-27-16 | Initiated | Citigroup | Buy |
| Jan-20-16 | Initiated | Credit Suisse | Outperform |
View All
Coherus Biosciences Inc Stock (CHRS) Latest News
What To Expect From Coherus BioSciences Inc (CHRS) Q1 2025 Earnings - GuruFocus
Coherus at The Citizens JMP Life Sciences: Strategic Oncology Focus By Investing.com - Investing.com Australia
Coherus at The Citizens JMP Life Sciences: Strategic Oncology Focus - Investing.com
Coherus to Report First Quarter 2025 Financial Results on May 12, 2025 - GlobeNewswire
Coherus Sets Q1 2025 Earnings Date: How to Join the May 12 Conference Call - Stock Titan
Coherus BioSciences Inc expected to post a loss of 21 cents a shareEarnings Preview - TradingView
Coherus to Participate in Upcoming Investor Conferences | CHRS S - GuruFocus
Coherus to Participate in Upcoming Investor Conferences | CHRS Stock News - GuruFocus
Coherus to Participate in Upcoming Investor Conferences - GlobeNewswire
Coherus BioSciences Sets Strong Presence at Top Healthcare Conferences: Key Oncology Updates Expected - Stock Titan
Coherus Presents Promising Early Clinical Data from Phase 1 Dose - GuruFocus
Coherus BioSciences Phase 1 Trial of CHS-114 Shows Confirmed Partial Response in Cancer Patient - marketscreener.com
Coherus reports promising cancer treatment results - Investing.com
Coherus (CHRS) Advances Clinical Trial for Anti-CCR8 Antibody in Cancer Treatment | CHRS Stock News - GuruFocus
Coherus Presents Promising Early Clinical Data from Phase 1 Dose Expansion Study of CHS-114 in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma at AACR 2025 - The Manila Times
Coherus BioSciences Reports Promising Clinical Data for CHS-114 Combined with Toripalimab in HNSCC and Gastric Cancer - Nasdaq
Breakthrough Cancer Treatment: Coherus Drug Shows Promise in Hard-to-Treat Head and Neck Cancer Patients - Stock Titan
Press Release Distribution & PR Platform - ACCESS Newswire
1 of Wall Street’s Favorite Stock with Impressive Fundamentals and 2 to Turn Down - The Globe and Mail
Coherus BioSciences announces CCO Paul Reider’s resignation By Investing.com - Investing.com India
Coherus BioSciences announces CCO Paul Reider’s resignation - Investing.com Australia
3 Reasons We Love Chart (GTLS) - The Globe and Mail
Coherus BioSciences: Cleaning The Balance Sheet And Developing New Drugs - Seeking Alpha
Coherus Marks Exit From Biosimilars By Completing Udenyca Divestment - insights.citeline.com
Coherus divests Udenyca franchise to Intas for up to $558.4m - MSN
Latham & Watkins Assists Coherus BioSciences in Obtaining CFIUS Clearance - Latham & Watkins LLP
Third Harmonic's shutdown, Coherus and Xoma drug sales connectedBizwomen - The Business Journals
Intas acquires Neulasta biosimilar Udenyca from Coherus BioSciences - World Pharmaceutical Frontiers
Big moves by small biotechs signal potential shift for investorsSan Francisco Business Times - The Business Journals
Coherus BioSciences (CHRS) Completes Divestiture of UDENYCA Fran - GuruFocus
Coherus BioSciences Completes Sale of Udenyca Franchise to Intas Pharmaceuticals for Up to $558.4 Million - marketscreener.com
Coherus completes strategic transformation - The Pharma Letter
Accord Biopharma Announces Completion Of Udenyca(Pegfilgrastim-Cbqv) Franchise Acquisition From Coherus Biosciences, Inc., Expanding U.S. Biosimilar Portfolio - marketscreener.com
Intas Pharmaceuticals Acquires UDENYCA Business from Coherus BioSciences - Contract Pharma
Accord BioPharma, Inc. Announces Completion of UDENYCA® (pegfilgrastim-cbqv) Franchise Acquisition from Coherus BioSciences, Inc., Expanding U.S. Biosimilar Portfolio - PR Newswire
Coherus Biosciences Completes UDENYCA Franchise Divestiture - TipRanks
Accord BioPharma, Inc. Announces Completion of UDENYCA® (pegfilgrastim-cbqv) Franchise Acquisition from Coherus BioSciences, Inc., Expanding U.S. Biosimilar Portfolio (PR Newswire) - Aktiellt
Coherus Completes Strategic Transformation with Successful Divestiture of UDENYCA® Franchise - GlobeNewswire
Coherus Lands Massive $558M Deal: Strategic Pivot to Oncology Extends Cash Runway to 2027 - Stock Titan
Coherus BioSciences (CHRS) Completes Divestiture of UDENYCA Franchise to Intas | CHRS Stock News - GuruFocus
Coherus BioSciences to Repurchase $170 Million Convertible Notes - MarketScreener
Coherus BioSciences to repurchase $170 million in convertible notes - Investing.com India
Coherus BioSciences To Buy Back $170 Mln Of 1.500% Convertible Sr. Subordinated Notes - Nasdaq
Coherus Announces Repurchase of Approximately $170 Million of Convertible Notes - Bluefield Daily Telegraph
Coherus Unveils Massive $230M Debt Reduction Plan, Starting With $170M Note Buyback - Stock Titan
Lacklustre Performance Is Driving Coherus BioSciences, Inc.'s (NASDAQ:CHRS) 27% Price Drop - simplywall.st
Coherus BioSciences : Block Advisors by H&R Block to Provide Timely Support for The Home Depot’s Pro Xtra Loyalty Members - MarketScreener
Coherus to Present Data from a Phase 1 Dose Expansion Study of CHS-114, a Cytolytic Antibody Targeting Chemokine Receptor 8 (CCR8), at the 2025 American Association for Cancer Research (AACR) Annual Meeting - The Manila Times
Coherus to Present Data from a Phase 1 Dose Expansion Study - GlobeNewswire
Breakthrough Cancer Treatment Data: Coherus' CCR8 Antibody Shows Promise in Head & Neck Cancer Trial - Stock Titan
Checkpoint inhibitor journey traces Chinese firms’ path to global revenue - BioWorld MedTech
Coherus Biosciences Inc Stock (CHRS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.84%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):